Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

被引：0
|
作者：
Raab, Marc S. [1 ]
Oriol, Albert [2 ]
Sandhu, Irwindeep [3 ]
White, Darrell [4 ,5 ]
Leblanc, Richard [6 ]
Raje, Noopur [7 ]
Ocio, Enrique M. [8 ]
Perrot, Aurore [9 ]
Facon, Thierry [10 ]
Rodriguez, Cesar [11 ]
Waesch, Ralph [12 ]
Amatangelo, Michael [13 ]
Zhou, Zehua [13 ]
Wang, Yue [13 ]
Civardi, Tiziana [14 ]
Koo, Phillip [13 ]
Maciag, Paulo [13 ]
Zhu, Daniell [13 ]
Katz, Jessica [13 ]
Richardson, Paul G. [15 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain
[3] Univ Alberta, Edmonton, AB, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[6] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Univ Lille, Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France
[11] Icahn Sch Med Mt Sinai, New York, NY USA
[12] Univ Freiburg, Dept Med, Med Ctr, Freiburg, Germany
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudr, Switzerland
[15] Dana Farber Canc Inst, Boston, MA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [41] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Kanagavel, Dheepak
    Gao, Lei
    Ziti-Ljajic, Samira
    Anderson, Kenneth C.
    BLOOD, 2017, 130
  • [42] Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
    Palumbo, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Lynch, M.
    Jou, Y-M
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
  • [43] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
    Jakubowiak, Andrzej J.
    Houisse, Ivan
    Majer, Istvan
    Benedict, Agnes
    Campioni, Marco
    Panjabi, Sumeet
    Ailawadhi, Sikander
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
  • [44] RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
    Jakubowiak, A. J.
    Martin, T.
    Singhal, S.
    Wang, M.
    Vij, R.
    Jagannath, S.
    Lonial, S.
    Kukreti, V.
    Buadi, F.
    Kunkel, L.
    Bray, L.
    Vallone, M.
    Orlowski, R. Z.
    Siegel, D. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 122 - 122
  • [45] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations
    Nadeem, Omar
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Creixenti, Joan Blade
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Sandberg, Anna
    Pelaez, Ivonne
    Jaques, Christian
    Orre, Marie
    Cavo, Michele
    BLOOD, 2020, 136
  • [46] Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
    Weisel, K.
    Palumbo, A.
    Chanan-Khan, A.
    Nooka, A. K.
    Spicka, I.
    Masszi, T.
    Beksac, M.
    Hungria, V.
    Munder, M.
    Mateos, M-V.
    Mark, T. M.
    Spencer, A.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Sonneveld, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael A.
    Tzachanis, Dimitrios
    Coleman, Morton
    Boccia, Ralph V.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
    Mikhael, Joseph
    Richardson, Paul G.
    Usmani, Saad Zafar
    Raje, Noopur S.
    Bensinger, William
    Dubin, Franck
    Liu, Qianying
    Vitse, Olivier
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
    van de Donk, Niels W. C. J.
    Popat, Rakesh
    Larsen, Jeremy
    Minnema, Monique C.
    Jagannath, Sundar
    Oriol, Albert
    Zonder, Jeffrey A.
    Richardson, Paul G.
    Rodriguez Otero, Paula
    Badros, Ashraf Z.
    Stadtmauer, Edward
    Bringhen, Sara
    Campagnaro, Erica
    Siegel, David S.
    Gamberi, Barbara
    Gironella Mesa, Mercedes
    Sonneveld, Pieter
    Tuong Vi Nguyen
    Di Micco, Antonia
    Sorrell, April
    Chen, Min
    Amatangelo, Michael
    Kueenburg, Elisabeth
    Lonial, Sagar
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
  • [50] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zamagni, Elena
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Creixenti, Joan Blade
    BLOOD, 2020, 136
12345